VOLUME 64   2003   SUPPLEMENT 12

Optimizing Pharmacologic Treatment of Psychotic Disorders

4 Expert Consensus Panel.
[PDF]

5 Introduction: Methods, Commentary, and Summary.
[Abstract] [PDF]

Guidelines

20 Guideline Organization and Key Terms.
[PDF]

I. MEDICATION SELECTION, DOSING, AND DOSE EQUIVALENCE

21 Guideline 1: Selecting Initial Pharmacologic Treatment for a Psychotic Disorder.

23 Guideline 2: Adequate Dose of Antipsychotics.

24 Guideline 3: Therapeutic Drug Monitoring (Using Plasma Levels).

24 Guideline 4: Duration of an Adequate Trial.

25 Guideline 5: Dose Equivalency.

27 Guideline 6: Dose Adjustment.

29 Guideline 7: Strategies When There Is an Inadequate Response.

35 Guideline 8: Pharmacologic Strategies for Managing Relapse.

37 Guideline 9: Dose Adjustment in Stable Patients.

38 Guideline 10: Managing Complicating Problems.

II. COMPLIANCE (ADHERENCE)

42 Guideline 11: Levels of Compliance.

42 Guideline 12: Assessing Compliance.

43 Guideline 13: When to Intervene for Compliance Problems.

43 Guideline 14: Strategies for Addressing Compliance Problems.

III. LONG-ACTING INJECTABLE ANTIPSYCHOTICS

46 Guideline 15: Benefits of Long-Acting Injectable Antipsychotics.

46 Guideline 16: Potential Disadvantages of Long-Acting Injectable Antipsychotics.

47 Guideline 17: Factors Favoring Use of Long-Acting Injectable Antipsychotics.

48 Guideline 18: Indications for Switching From an Oral Antipsychotic to a Long-Acting Injectable Atypical.

49 Guideline 19: Factors Motivating Patients to Return for Repeat Injections.

IV. DEFINING REMISSION AND RECOVERY

50 Guideline 20: Indicators of Remission and Recovery.

51 Guideline 21: Severity and Duration of Symptoms as Indicators of Remission and Recovery.

SURVEY RESULTS

52 Expert Survey Results and Guideline References.
[PDF]

CME Section

95 Commentary: Expert Consensus Guidelines for Optimizing Pharmacologic Treatment of Psychotic Disorders.
[PDF]

98 CME Posttest.
[PDF]

100 CME Registration Form.
[PDF]